MaxCyte Inc - Asset Resilience Ratio
MaxCyte Inc (MXCT) has an Asset Resilience Ratio of 43.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MaxCyte Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how MaxCyte Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MaxCyte Inc (MXCT) total assets.
Liquid Assets Composition Over Time
This chart breaks down MaxCyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore MaxCyte Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $92.75 Million | 43.45% |
| Total Liquid Assets | $92.75 Million | 43.45% |
Asset Resilience Insights
- Very High Liquidity: MaxCyte Inc maintains exceptional liquid asset reserves at 43.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MaxCyte Inc Industry Peers by Asset Resilience Ratio
Compare MaxCyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for MaxCyte Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for MaxCyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.87% | $126.60 Million | $239.47 Million | +7.47pp |
| 2023-12-31 | 45.39% | $121.78 Million | $268.27 Million | -30.05pp |
| 2022-12-31 | 75.45% | $216.28 Million | $286.65 Million | +2.50pp |
| 2021-12-31 | 72.95% | $207.26 Million | $284.12 Million | +42.03pp |
| 2020-12-31 | 30.91% | $16.01 Million | $51.78 Million | +25.92pp |
| 2019-12-31 | 5.00% | $1.50 Million | $29.99 Million | -8.15pp |
| 2018-12-31 | 13.15% | $3.19 Million | $24.27 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more